logo
Share SHARE
FONT-SIZE Plus   Neg

XenoPort Gets U.S. Patent Directed To Composition And Formulations Of XP23829

XenoPort Inc. (XNPT) said it was awarded U.S. Patent 8,148,414 for "Prodrugs of Methyl Hydrogen Fumarate, Pharmaceutical Compositions Thereof, and Methods of Use." Subject to potential Hatch-Waxman patent term extensions, the term of the patent extends until 2029.

The patent is directed to the XP23829 compound, analogs thereof and formulations thereof, XenoPort added. A related U.S. patent application directed to therapeutic uses of XP23829 is currently pending. XP23829 is a prodrug of methyl hydrogen fumarate, also called as monomethyl fumarate or MMF. In cell- and animal-based models, MMF has been shown to exhibit immuno-modulatory properties and inhibit damage from oxidative stress.

XenoPort, which owns all rights to XP23829, plans to file an Investigational New Drug Application for XP23829 for the treatment of relapsing remitting MS with the U.S. Food and Drug Administration in the second quarter of 2012 and expects to initiate human clinical trials later this year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After moving sharply higher at the open, stocks continue to see notable strength in mid-day trading on Wednesday. Buying interest has waned from earlier in the session, however, leading the major averages to pull back well off their highs. Former Florida Gov. Jeb Bush and businessman Donald Trump top the list of Republican presidential candidates in a new CNN/ORC International poll, although both are well behind Hillary Clinton in potential general election matchups. Confusion refuses to die down in Europe even after crucial deadlines were missed and hapless Greeks stare into an uncertain future for their country, while other Europeans try to preserve the sanctity of the union and the euro.
comments powered by Disqus
Follow RTT